SCHEMBL6159894

SCHEMBL6159894

[CH2]CC(=C)c1cc2ccccc2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 3/20 0.56
KDM4E B2RXH2 5/20 0.55
HSD17B10 Q99714 2/20 0.55
MAPT P10636 1/20 0.55
DAO P14920 1/20 0.55
HPGD P15428 1/20 0.55
SRD5A2 P31213 1/20 0.55
ALDH1A1 P00352 2/20 0.53
GAA P10253 1/20 0.53
MAPK1 P28482 1/20 0.53
IDO1 P14902 2/20 0.50
LMNA P02545 2/20 0.46
PDGFRB P09619 2/20 0.46
PDGFRA P16234 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TP53 P04637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
DRD2 P14416 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20937445 0.84 FLT3 (0.55) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL5653870 0.80 FLT3 (0.64) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL8243662 0.79 KDM4E (0.66) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL8154270 0.77 FLT3 (0.60) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL30592039 0.77 FLT3 (0.60) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL30075078 0.75 KDM4E (0.66) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL5641252 0.74 KDM4E (0.70) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL638981 0.73 FLT3 (0.71) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL2190744 0.73 KDM4E (0.68) FLT3KDM4EHSD17B10MAPTDAO
SCHEMBL20861119 0.73 FLT3 (0.55) FLT3KDM4EHSD17B10MAPTDAO

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1505156-B1 Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester CONSORTIUM ELEKTROCHEM IND (DE) 2005-12-07 EP disclosed
US-20050032182-A1 Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters CONSORTIUM FUR ELEKTROCHEMISCHE INDUSTRIE GMBH 2005-02-10 US disclosed
EP-1505156-A1 Process for the enantioselective preparation of secondary alcohols by lipase catalysed solvolysis of the corresponding acetoacetic acid ester Consortium für elektrochemische Industrie GmbH (DE) 2005-02-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032182-A1 Process for the enantioselective preparation of secondary alcohols by lipase-catalyzed solvolysis of the corresponding acetoacetic esters LIPC, LIPE, LIPA FLT3 4529/4885KDM4E 4077/4885HSD17B10 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.